IN2014DN10123A - - Google Patents

Info

Publication number
IN2014DN10123A
IN2014DN10123A IN10123DEN2014A IN2014DN10123A IN 2014DN10123 A IN2014DN10123 A IN 2014DN10123A IN 10123DEN2014 A IN10123DEN2014 A IN 10123DEN2014A IN 2014DN10123 A IN2014DN10123 A IN 2014DN10123A
Authority
IN
India
Prior art keywords
vectors
methods
dcs
transgene
transcription
Prior art date
Application number
Inventor
Emeline Sarry
Cécile Bauche
Original Assignee
Theravecty S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravecty S filed Critical Theravecty S
Publication of IN2014DN10123A publication Critical patent/IN2014DN10123A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the insertion of a promoter sequence from an MHC class I gene promoter into a lentiviral vector in order to direct the transcription of a transgene, which preferably encodes an immunogenic polypeptide to be expressed in a mammalian cell host, preferably APC (DCs). The invention encompasses these vectors , methods of making the vectors , and methods of using them , including medicinal uses.
IN10123DEN2014 2012-05-23 2013-04-30 IN2014DN10123A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305566.7A EP2666477A1 (en) 2012-05-23 2012-05-23 Lentiviral vectors containing an MHC class I promoter
PCT/EP2013/059041 WO2013174630A1 (en) 2012-05-23 2013-04-30 Lentiviral vectors containing an mhc class i promoter

Publications (1)

Publication Number Publication Date
IN2014DN10123A true IN2014DN10123A (en) 2015-08-21

Family

ID=48289150

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10123DEN2014 IN2014DN10123A (en) 2012-05-23 2013-04-30

Country Status (18)

Country Link
US (1) US8951535B2 (en)
EP (2) EP2666477A1 (en)
JP (1) JP5938143B2 (en)
KR (1) KR101774929B1 (en)
CN (1) CN104736167B (en)
AU (1) AU2013265586B2 (en)
BR (1) BR112014028944B1 (en)
CA (1) CA2873473C (en)
ES (1) ES2498277T3 (en)
HK (1) HK1211837A1 (en)
IL (1) IL235705A (en)
IN (1) IN2014DN10123A (en)
NZ (1) NZ702345A (en)
PL (1) PL2678032T3 (en)
PT (1) PT2678032E (en)
SG (1) SG11201407732SA (en)
WO (1) WO2013174630A1 (en)
ZA (1) ZA201408652B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015030211A2 (en) * 2013-06-03 2017-08-22 Theravectys LENTIVIRAL VECTORS CONTAINING A CLASS I MHC, CLASS II MHC, OR BETA-2 MICROGLOBULIN BETWEEN PROMOTER SEQUENCE
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
KR20220005208A (en) 2020-07-06 2022-01-13 주식회사 지씨셀 A Novel Cell for Transplantation with Reduced Immunogenicity
CN114107393A (en) 2021-04-07 2022-03-01 上海劲威生物科技有限公司 Lentiviral vector and lentiviral particle for treating hepatitis B as well as preparation methods and applications of lentiviral vector and lentiviral particle
KR20240073177A (en) * 2022-11-10 2024-05-24 전남대학교산학협력단 Pharmaceutical composition for preventing or treating glioma comprising multiple epitope peptide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19720152A1 (en) * 1997-05-02 1998-11-05 Max Delbrueck Centrum Retroviral vector system for gene therapy
FR2777909B1 (en) 1998-04-24 2002-08-02 Pasteur Institut USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES
ES2447115T3 (en) 1999-10-11 2014-03-11 Institut Pasteur Vectors for the preparation of immunotherapeutic compositions
DE60033045T2 (en) 1999-10-12 2007-11-08 Institut Pasteur LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA
FR2870126B1 (en) 2004-05-17 2009-07-17 Pasteur Institut RECOMBINANT LENTIVIRAL VECTOR FOR EXPRESSION OF FLAVIVIRIDAE PROTEIN AND ITS APPLICATIONS AS VACCINE
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
BRPI0813194B8 (en) 2007-08-03 2021-05-25 Centre Nat Rech Scient kit, lentiviral vector particles, composition of plasmid vectors, chimeric hiv-1 derived antigen, vsv-g envelope protein, nucleic acid molecules, immunogenic composition and use of a lentiviral vector

Also Published As

Publication number Publication date
WO2013174630A1 (en) 2013-11-28
SG11201407732SA (en) 2014-12-30
CN104736167B (en) 2018-07-27
JP5938143B2 (en) 2016-06-22
ZA201408652B (en) 2016-09-28
KR20150014472A (en) 2015-02-06
US20140120132A1 (en) 2014-05-01
US8951535B2 (en) 2015-02-10
HK1211837A1 (en) 2016-06-03
PL2678032T3 (en) 2014-11-28
PT2678032E (en) 2014-09-09
EP2678032B1 (en) 2014-06-18
CN104736167A (en) 2015-06-24
IL235705A0 (en) 2015-01-29
CA2873473C (en) 2019-05-07
AU2013265586B2 (en) 2015-09-03
EP2666477A1 (en) 2013-11-27
CA2873473A1 (en) 2013-11-28
EP2678032A1 (en) 2014-01-01
BR112014028944A2 (en) 2015-09-29
AU2013265586A1 (en) 2014-12-11
IL235705A (en) 2016-10-31
ES2498277T3 (en) 2014-09-24
KR101774929B1 (en) 2017-09-19
JP2015518716A (en) 2015-07-06
NZ702345A (en) 2016-03-31
BR112014028944B1 (en) 2020-11-10

Similar Documents

Publication Publication Date Title
PH12018501628A1 (en) Optimized factor viii genes
MX2021006932A (en) Engineered high-affinity human t cell receptors.
MX2018010483A (en) Immunogens for hiv vaccination.
MX2018010616A (en) Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same.
MX365435B (en) Methods of host cell modification.
PE20142406A1 (en) ANTIGENS ASSOCIATED WITH PROSTATE AND VACCINE-BASED IMMUNOTHERAPY REGIMES
IN2014CN03468A (en)
MX2015014423A (en) Effective delivery of large genes by dual aav vectors.
MX2014004598A (en) Alpha-amylase variants and polynucleotides encoding same.
MX2014004539A (en) Alpha-amylase variants and polynucleotides encoding same.
NZ602278A (en) Bluetongue virus recombinant vaccines and uses thereof
IN2014DN10123A (en)
GB0917002D0 (en) Improved shigella blebs
MX2013004353A (en) Recombinant n-propanol and isopropanol production.
MX363427B (en) Psicose epimerase mutant and method for preparing psicose by using same.
MX2018010288A (en) Transposon system and methods of use.
WO2013060819A3 (en) Transient expression vectors, preparation and uses thereof
EP3998341A3 (en) Adenoviral vectors
GB201017519D0 (en) Vaccines
PH12015502353A1 (en) Fusion polypeptides and vaccines
IN2015DN03206A (en)
IN2014DN10111A (en)
GB201113499D0 (en) Expression of transcription factor encoding genes
MD20130099A2 (en) Recombinant expression of soluble interferon
MX2017004769A (en) Promoter and regulatory elements for improved expression of heterologous genes in host cells.